我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
11
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
9
81.8%
招募中
1
9.1%
终止
暂无批准数据
- QuidelOrtho announced plans to acquire LEX Diagnostics for approximately $100 million following FDA 510(k) clearance, expected in late 2025 or early 2026. - The company will discontinue its Savanna platform development based on recent clinical trial results and strategic portfolio realignment decisions. - LEX Diagnostics' ultra-fast molecular platform can deliver positive results for Flu A, Flu B, and COVID-19 detection in approximately six minutes. - The acquisition aims to strengthen QuidelOrtho's presence in point-of-care molecular diagnostics, described as one of the largest and fastest-growing diagnostic segments.